Minimizing and Managing Toxicities to Maintain Patients on BTK Inhibitor Therapy

Help keep your patients on BTK inhibitor treatment with this online AE management tool, supported by an expert commentary, and a downloadable resource for clinicians to discuss with patients.
Jeremy S. Abramson, MD, MMSc
Farrukh T. Awan, MD
Christopher R. Flowers, MD, MS
John P. Leonard, MD
Julie M. Vose, MD, MBA

ClinicalThought

With the approval and clinical availability of BTK inhibitors, are you effectively managing the associated toxicities in your patients with lymphomas to get the most out of these agents?

Jeremy S. Abramson, MD, MMSc Released: March 8, 2019

Downloadable Resource

A free resource guide for patients who are receiving BTK inhibitors, including information on FDA approvals, dosing, and potential side effects.

Released: June 20, 2019

Interactive Decision Support Tool

Use this Interactive Decision Support Tool to see strategies to assess and manage adverse events associated with BTK inhibitors from 5 renowned experts in hematologic malignancies.

Jeremy S. Abramson, MD, MMSc Farrukh T. Awan, MD Christopher R. Flowers, MD, MS John P. Leonard, MD Julie M. Vose, MD, MBA Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: September 10, 2019 Expired: No longer available for credit
Jointly provided by Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Melissa Velasquez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

Supported by educational grants from
AstraZeneca
Pharmacyclics LLC, an AbbVie Company
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue